Amgen Inc. has announced that , its newest experimental ovarian cancer drug, trebananib, has failed in its medical trial stage at improving the survival rate of late-stage ovarian cancer patients. This anti-tumor treatment drug is designed to be administered together with paclitaxel, a chemotherapy drug. During the study’s Phase 3, doctor’s evaluated both the safety of administration and the … [Read more...]
You are here: Home / Archives for amgen survival trial